ArticleBMC pediatrics2026
MiR-483-5p has the potential to serve as a biomarker in perioperative respiratory adverse events in children under general anesthesia.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPerioperative respiratory adverse events (PRAE) may cause critical illness in children undergoing anesthesia and surgery. So, this study aims to explore the diagnostic value of miR-483-5p in PRAE.
methodsThis study included 112 patients with PRAE and 93 patients without PRAE. MiR-483-5p expression was quantified utilizing RT-qPCR. The receiver operating characteristic (ROC) curve was utilized to assess the diagnostic value. The clinicopathological characteristics of PRAE and miR-483-5p level were analyzed by the Chi-squared test. Risk factors for PRAE were analyzed using multivariate logistic regression. The multicellular human alveolar model was established by treating it with lipopolysaccharide (LPS) at 48 h. Then, cell viability and inflammatory factors were detected in the PRAE model by cell counting kit-8 (CCK-8) assay and ELISA.
resultsMiR-483-5p was obviously increased and had high diagnostic value in PRAE. In PRAE, miR-483-5p was a risk factor and was closely related to clinical indicators. In the multicellular human alveolar model, overexpression of miR-483-5p reduced proliferation and elevated inflammatory factors levels, while inhibition of miR-483-5p increased proliferation and reduced inflammatory factors levels, which is consistent with the trend in the PRAE cell model.
conclusionMiR-483-5p might participate in PRAE in children by regulating proliferation and inflammatory factors, proving that it may be a biomarker in PRAE. In addition, miR-483-5p was a risk factor for PRAE. In the multicellular human alveolar model, LPS treatment significantly enhanced miR-483-5p expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.